Mablink
is a France-based biotechnology company that develops antibody-drug conjugates for the treatment of cancer... Read moreMablink
is a France-based biotechnology company that develops antibody-drug conjugates for the treatment of cancer... Read more
News
Oct 23, 2023
LaingBuisson
Mablink: France: Eli Lilly to acquire Mablink Bioscience
Mar 14, 2023
Benzinga
Mablink: Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023
Oct 17, 2022
Tech Funding News
Mablink: Mablink Bioscience secures 31M to develop better treatment for cancer patients
Oct 14, 2022
BioSpace
Mablink: Mablink Breaks into ADC Space with $30M for Improved Linker Tech
Mar 15, 2022
FirstWord Pharma
Mablink: Mablink Bioscience Appoints Its Head of Preclinical R&D
Mar 01, 2022
FirstWord Pharma
Mablink: Mablink Bioscience appoints its Chief Development Officer
Oct 21, 2021
FinanzNachrichten
Mablink: Mablink Bioscience S.A.S.: Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy
Apr 27, 2021
BioSpace
Mablink: Mablink Bioscience, the next generation ADC company, raises 4 Million to move forward its ADC pipeline targeted at cancers with high unmet medical needs
